# EDGAR Filing Document

**Accession Number:** 0001015823
**File Stem:** 0001641172-25-017411
**Filing Date:** 2025-7
**Character Count:** 15515
**Document Hash:** 4ce52ee030c5d15d70a38dc44e760107
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-017411.hdr.sgml**: 20250701

**ACCESSION NUMBER**: 0001641172-25-017411

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250701

**DATE AS OF CHANGE**: 20250701

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVIVA PHARMACEUTICALS HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001742927
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90624
- **FILM NUMBER:** 251097838

**BUSINESS ADDRESS:**
- **STREET 1:** 10080 N WOLFE ROAD
- **STREET 2:** SUITE SW3-200
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014
- **BUSINESS PHONE:** 4085018881

**MAIL ADDRESS:**
- **STREET 1:** 10080 N WOLFE ROAD
- **STREET 2:** SUITE SW3-200
- **CITY:** CUPERTINO
- **STATE:** CA
- **ZIP:** 95014

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tenzing Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180606
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SAXENA PARAG
- **CENTRAL INDEX KEY:** 0001015823

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 250 WEST 55TH STREET, SUITE 13D
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 10)**

**REVIVA PHARMACEUTICALS HOLDINGS, INC.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value**

*(Title of Class of Securities)*

**76152G100**

*(CUSIP Number)*

**Parag Saxena**<br>Vedanta Management, L.P.,<br>250 West 55th Street, Ste 13D<br>New York NY 10019<br>212-710-5220

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/27/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **76152G100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Vedanta Associates, L.P.** | Name of reporting person<br>**Vedanta Associates, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3408401.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3408401.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3408401.00** | Aggregate amount beneficially owned by each reporting person<br>**3408401.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.8%** | Percent of class represented by amount in Row (11)<br>**4.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** See Item 5 for additional information.

| **CUSIP No.** | **76152G100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**VEDANTA PARTNERS, LLC** | Name of reporting person<br>**VEDANTA PARTNERS, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5367069.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5367069.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5367069.00** | Aggregate amount beneficially owned by each reporting person<br>**5367069.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.5%** | Percent of class represented by amount in Row (11)<br>**7.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** See Item 5 for additional information.

| **CUSIP No.** | **76152G100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Parag Saxena** | Name of reporting person<br>**Parag Saxena** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**K7** | Citizenship or place of organization<br>**K7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**892737.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5376169.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**892737.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5367069.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6259806.00** | Aggregate amount beneficially owned by each reporting person<br>**6259806.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.7%** | Percent of class represented by amount in Row (11)<br>**8.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** See Item 5 for additional information.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value

**(b) Name of Issuer:**
REVIVA PHARMACEUTICALS HOLDINGS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
Vedanta Management, L.P., 250 West 55th Street, Ste 13D, New York, NY, 10019

This Amendment No. 10 to Schedule 13D (this "Amendment No. 10") filed on behalf of Parag Saxena, Vedanta Partners, LLC ("Vedanta Partners"), Vedanta Associates, L.P. ("Vedanta Associates" and collectively, the "Reporting Persons") amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on September 4, 2018, as amended and supplemented by Amendment No. 1, Amendment No. 2 and Amendment No. 3 on January 19, 2021, Amendment No. 4 on June 3, 2021, Amendment No. 5 on September 12, 2022, Amendment No. 6 on November 30, 2023, Amendment No. 7 on May 31, 2024, Amendment No. 8 on August 23, 2024 and Amendment No. 9 on January 31, 2025 (as amended, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 10 does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in rows 11 and 13 of the cover pages to this Amendment No.  10 are incorporated by reference into this Item 5. The percentages set forth in row 13  of each cover page are based on 68,003,613 outstanding shares of common stock, par  value $0.0001 per share ("Common Stock"), of Reviva Pharmaceuticals Holdings, Inc.,  a Delaware corporation (the "Issuer"), as of July 1, 2025, as reported directly by the  Issuer to the Reporting Persons.

**(b)**
The information set forth in rows 7 through 10 of the cover pages to this Amendment  No. 10 is incorporated by reference.

The 3,408,401 shares of Common Stock reported as beneficially owned on this  Amendment No. 10 by Vedanta Associates consist of the following: (i) 99,539 shares  of Common Stock held directly, (ii) 399,000 shares of Common Stock held by Beta  Operators Fund, L.P. ("Beta Operators"), (iii) 869,565 shares of Common Stock  underlying warrants held by Beta Operators, (iv) 585,366 shares of Common Stock  underlying warrants held by Vedanta R2 Partners, LP ("Vedanta R2"), (v) 869,565  shares of Common Stock underlying pre-funded warrants held by Beta Operators, and  (vi) 585,366 shares of Common Stock underlying pre-funded warrants held by Vedanta  R2. As a result, Vedanta Associates is deemed to beneficially own 4.8% of the  outstanding shares of Common Stock of the Issuer as of July 1, 2025 (the "Filing Date").  The securities beneficially owned by Vedanta Associates excludes 299,250 shares of  Common Stock issuable upon the exercise of 399,000 warrants held by Beta Operators  which contain an issuance limitation that prohibits the holder from exercising the  warrants to the extent that after giving effect to such issuance after exercise, the holder  (together with the holder's affiliates and any other persons acting as a group together  with the holder or any of the holder's affiliates, including the other Reporting Persons)  would beneficially own in excess of 4.99% of the shares of Common Stock outstanding  immediately after giving effect to the issuance of the shares of Common Stock issuable  upon exercise of the warrants (the "Blocker").

The 5,367,069 shares of Common Stock reported as beneficially owned on this  Amendment No. 10 by Vedanta Partners consist of the following: (i) 931,000 shares of  Common Stock held by Vedanta Associates-R, L.P. ("Vedanta Associates-R"), (ii)  399,000 shares of Common Stock held by Beta Operators, (iii) 99,539 shares of  Common Stock held by Vedanta Associates, (iv) 513,834 shares of Common Stock  underlying warrants held by Vedanta Associates-R, (v) 869,565 shares of Common  Stock underlying warrants held by Beta Operators, (vi) 585,366 shares of Common  Stock underlying warrants held by Vedanta R2, (vii) 513,834 shares of Common Stock  underlying pre-funded warrants held by Vedanta Associates-R, (vii) 869,565 shares of  Common Stock underlying pre-funded warrants held by Beta Operators, and (viii)  585,366 shares of Common Stock underlying pre-funded warrants held by Vedanta R2.  As a result, Vedanta Partners is deemed to beneficially own 7.5% of the outstanding  shares of Common Stock of the Issuer as of the Filing Date.

 The 6,269,806 shares of Common Stock reported as beneficially owned on this  Amendment No. 10 by Mr. Saxena consist of the following: (i) 871,337 shares of  Common Stock held directly, (ii) 931,000 shares of Common Stock held by Vedanta  Associates-R, (iii) 399,000 shares of Common Stock held by Beta Operators, (iv)  99,539 shares of Common Stock held by Vedanta Associates, (v) 513,834 shares of  Common Stock underlying warrants held by Vedanta Associates-R, (vi) 869,565 shares  of Common Stock underlying warrants held by Beta Operators, (vii) 585,366 shares of  Common Stock underlying warrants held by Vedanta R2, (viii) 513,834 shares of  Common Stock underlying pre-funded warrants held by Vedanta Associates-R, (vii)  869,565 shares of Common Stock underlying pre-funded warrants held by Beta  Operators, (ix) 585,366 shares of Common Stock underlying pre-funded warrants held  by Vedanta R2, and (x) 21,400 underlying options that are fully vested as of the Filing  Date. As a result, Mr. Saxena is deemed to beneficially own 8.7% of the outstanding  shares of Common Stock of the Issuer as of the Filing Date. The securities beneficially  owned by Mr. Saxena exclude 8,200 shares underlying options that are unvested as of  60 days of the Filing Date.

In accordance with Rule 13d-3, the beneficial ownership percentage for each Reporting  Person assumes that the warrants and options that can be exercised within 60 days of  the Filing Date, if any, held by such Reporting Person have been exercised, and that  no other warrants or options have been exercised.

**(c)**
The Reporting Persons have not effected any transactions during the past sixty (60)  days from the date of this filing in any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Vedanta Associates, L.P.

**Signature:** By: Vedanta Partners, LLC, the GP of Vedanta Associates, L.P. /s/ Parag Saxena

**Name/Title:** Parag Saxena/CEO of Vedanta Partners, LLC

**Date:** 07/01/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** VEDANTA PARTNERS, LLC

**Signature:** /s/ Parag Saxena

**Name/Title:** Parag Saxena/CEO

**Date:** 07/01/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Parag Saxena

**Signature:** /s/ Parag Saxena

**Name/Title:** Parag Saxena/Individual

**Date:** 07/01/2025